Small Molecule GCSFR Agonists Avoiding Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hematopoietic and neurological disorders associated with the granulocyte colony-stimulating factor receptor (GCSFR) lack effective small molecule therapies, with existing compounds either failing to selectively activate the receptor or causing unwanted antibody production.
Innovation Solution
Development of compounds, such as those represented by Formulas (I), (II), (III), and (VI), which modulate the activity of the GCSFR, acting as agonists or partial agonists to treat disorders like granulocytopenia, neutropenia, and neurological conditions, while avoiding direct competition with endogenous GCSF and minimizing antibody induction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds are used to activate GCSFR, then receptor activation is achieved, but unwanted antibody production occurs
Solution Approach 1:
The patent uses small molecule compounds as intermediaries to activate the GCSFR receptor indirectly rather than using protein-based therapies. These small molecules bind to and activate the receptor without being recognized as foreign antigens, thereby avoiding antibody production while still achieving reliable receptor activation and therapeutic effect.
2Reliability
If protein-based GCSF is used to treat hematopoietic disorders, then therapeutic effect is achieved, but species-specific cross-reactivity and antibody formation occur
Solution Approach 1:
The patent employs small molecule compounds instead of large protein-based GCSF. These small molecules are structurally simple, do not elicit immune responses, and avoid the cross-reactivity issues associated with species-specific protein differences. They provide reliable therapeutic effects without the harmful immunogenic effects of protein-based therapies.
3Object-generated harmful factors
If small molecule compounds are developed to activate GCSFR, then antibody production is minimized, but selective activation of the receptor is challenging
Solution Approach 1:
The patent optimizes specific molecular parameters of the small molecule compounds, including the substitution patterns on aromatic rings (R1-R6 groups), the linker structure (L1), and the heterocyclic core (Q). By systematically varying these structural parameters, the invention achieves compounds that selectively activate human GCSFR with high precision while minimizing off-target effects and antibody production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds selectively activate the GCSFR, providing therapeutic benefits for hematopoietic and neurological disorders without the drawbacks of existing treatments, such as antibody production, and demonstrate species-specific activity profiles.
Implementation Method 1
compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCSFR)... compounds selectively activate the GCSFR
Data Source
AI summary
Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders.